Treatment Horizons in Bipolar Disorder: Stem Cells and Pharmacology
John R. Kelsoe, MD Keynote presentation at the 6th Annual Prechter Lecture November 12, 2012 prechterfund.orgFrom:DepressionCenterViews:2 0ratingsTime:55:24More inScience Technology
Read the original here:
Treatment Horizons in Bipolar Disorder: Stem Cells and Pharmacology - Video
The Principles of Regulation and the Progress of Research
Carl Schneider, Ph.D. Presented at the 6th Annual Prechter Lecture - "Stem Cells and Ethics" November 12, 2012 prechterfund.orgFrom:DepressionCenterViews:0 0ratingsTime:34:23More inScience Technology
Read more here:
The Principles of Regulation and the Progress of Research - Video
Heather Persuasive Speech
Heather Schenkler Calls for more Stem Cells Research FundingFrom:FeaturedSpeechesViews:0 0ratingsTime:09:05More inEducation
Originally posted here:
Heather Persuasive Speech - Video
Embryonic Stem Cells vs. Adult Stem Cells
Fourth speech Persuasive speechFrom:Karrie AndersonViews:0 0ratingsTime:07:40More inPeople Blogs
What Is A Stem Cell And How Do Stem Cells Work
What is a Stem Cell? How do Stem Cells work? http://www.stem-cellnutrition.com Natural Health Alternative Remedies like stem cell nutrition are helping people to become healthier. http Watch this video to learn what are stem cells, how do adult stem cells work and uses of how does they aid to improve a person #39;s health. Learn how stem cells play as your master cells that have the ability and form to become any cell in the body like liver, heart, muscle, joint, brain cells and even your eye cells. They are present when you are born and adult stem cells are your natural renewal system helping keep your body healthy so providing you with natural health. Why are stem cells important? I will go over this in this video and also show you how do stem cells work like for instance if a tissue is affected in your body it will signal the bone marrow to release adult stem cells into your blood stream and then will end up helping the natural renewal system of the tissue so your body remains healthy and not worn down. This is important when it comes to the aging process because the cell numbers decrease in age. http://www.stem-cellnutrition.com So how do you maintain your health and wellness? I do it by a stem cell enhancer product called stem enhance along with other stemenhance products to increase my health and set a goal for myself to obtain optimal health.From:Jennifer MarksViews:2 0ratingsTime:02:31More inHowto Style
Follow this link:
What Is A Stem Cell And How Do Stem Cells Work - Video
Stem cell banking
Stem cells can be used to treat a broad array of diseases and ailments, find out how they may be used in the future. Vinn Singh, Founder and CEO of Next Healthcare Inc. talks about this new technology.From:StudioOneUNDViews:4 0ratingsTime:06:16More inScience Technology
Beginner #39;s Luck
A brief introduction into embryonic stem cells - what they are and what they can be used for. Weizmann Institute scientists are able to conduct cutting-edge research on stem cells thanks to the Helen and Martin Kimmel Institute for Stem Cell Research. Copyright © Weizmann Institute of ScienceFrom:WeizmannCanadaViews:0 0ratingsTime:03:15More inScience Technology
The rest is here:
Beginner's Luck - Video
Stem Cells and Insurance
The current state of the economy is uncertain and cause for concern for any business. Stem cell banks are no exception. When banks close down for any reason, its customers are immediately outraged about the money they have deposited. In the event of a stem cell bank failure, the investment is much more precious. These cells are of great interest in research because of their immense potential in regenerative medicine and other applications. A contingency plan needs to be implemented in order to protect these resources that are being used to find valuable treatments for otherwise incurable diseases.From:Alexandra KellyViews:2 0ratingsTime:02:53More inPeople Blogs
Go here to read the rest:
Stem Cells and Insurance - Video
Life UnLtd, Charis Thompson, Three Times a Woman A Gendered Economy of Stem Cell Innovation Pt 2
This presentation was part of CSW #39;s Life (Un)Ltd project, and took place on October 24, 2012. Life (UnLtd) is an interdisciplinary project initiated by CSW Associate Director Rachel Lee that engages recent developments in biosciences and biotechnology, foregrounding critical, aesthetic, and ethics-based approaches to what have become global research and marketing industries.From:UCLAViews:16 0ratingsTime:27:24More inEducation
Life Un(Ltd), Charis Thompson, Three Times a Woman- A Gendered Economy of Stem Cell Innovation Pt 1
This presentation was part of CSW #39;s Life (Un)Ltd project, and took place on October 24, 2012. Life (UnLtd) is an interdisciplinary project initiated by CSW Associate Director Rachel Lee that engages recent developments in biosciences and biotechnology, foregrounding critical, aesthetic, and ethics-based approaches to what have become global research and marketing industries.From:UCLAViews:19 0ratingsTime:36:53More inEducation
Originally posted here:
Life Un(Ltd), Charis Thompson, Three Times a Woman- A Gendered Economy of Stem Cell Innovation Pt 1 - Video
SCMOM 2012_NeoStem
NeoStem, Inc. is an emerging technology leader in the fast-developing cell therapy market. Its business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC, with a medically important cell therapy product development program. NeoStem #39;s most clinically advanced therapeutic, AMR-001, is being developed at its Amorcyte subsidiary, which is enrolling patients in a Phase 2 trial for preservation of heart function after a heart attack. Athelos Corporation, also a NeoStem subsidiary, is in early stage clinical exploration of a T-cell therapy for autoimmune conditions. Pre-clinical assets include our VSELTM Technology platform and our mesenchymal stem cell product candidate for regenerative medicine. http://www.neostem.com Presenter: Jonathan Sackner-Bernstein, NeoStem, Inc.From:AllianceRegenMedViews:4 1ratingsTime:14:54More inScience Technology
Excerpt from:
SCMOM 2012_NeoStem - Video
SCMOM 2012_Stanford Cardiovascular Institute
Stanford Cardiovascular Institute (CVI) is the nucleus for cardiovascular research at Stanford University. Formed in 2004, the Cardiovascular Institute is home to Stanford #39;s myriad cardiovascular-related adult and pediatric research, clinical, and educational programs, centers and laboratories, as well as over 500 Stanford basic scientists, graduate students, clinician scientists, and other researchers in heart and vessel disease and prevention. Within the area of cardiac regenerative medicine, the Stanford CVI has significant research endeavors involving human pluripotent stem cells for (1) cardiovascular disease modeling, (2) drug screening and discovery, and (3) personalized cell therapy. Recently, Stanford CVI investigators received a $20 million CIRM Disease Team Therapy Award for performing pre-IND work that would enable the first-in-man clinical trial involving injection of human embryonic stem cell-derived cardiomyocytes for patients with heart failure. wulab.stanford.edu Presenter Joseph Wu, Associate Professor, Cardiovascular Medicine, Stanford University School of MedicineFrom:AllianceRegenMedViews:3 0ratingsTime:17:06More inScience Technology
Read more here:
SCMOM 2012_Stanford Cardiovascular Institute - Video
SCMOM 2012_Regen BioPharma, Inc.
The Regen BioPharma business model is to take multiple stem cell therapeutics to and through the human "safety and signal of efficacy" stage (Phase I/II clinical trials). The approach is a highly focused analysis of issued patents in regenerative medicine, identification and acquisition of undervalued assets that have demonstrated proof of concept, and forming companies around these assets. Having assembled a core infrastructure specialized in obtaining regulatory approval and executing clinical trials in cell therapy, we aim to act as a "superincubator" that within 18 - 24 months grows technologies from laboratory to an asset ready for spin-off or sale to feed the pipeline of Big Pharma. http://www.regenbiopharma.com Presenter: J. Christopher Mizer, President, Regen BioPharma, Inc.From:AllianceRegenMedViews:4 1ratingsTime:09:13More inScience Technology
Washington, November 28 (ANI): When mesenchymal cells derived from skeletal muscle (SM-MSCs) or adipose tissue (ADSCs) were injected into the heart muscle (myocardium) of separate groups of laboratory rats that had suffered a myocardial infarction, rats in both groups experienced significantly improved left ventricle function and smaller infarct size after cell therapy, a study has found.
The study, carried out by researchers at Oslo University Hospital and the Norwegian Center for Stem cell Research, Oslo University, sought to determine if MSCs from different organs would result in different functional outcomes.
"Despite advances in revascularization and medical therapy, acute myocardial infarction (AMI) and heart failure are still important causes of morbidity and mortality in industrialized countries," said study co-author Dr. Jan E. Brinchmann of the Norwegian center for Stem Cell Research at Oslo University Hospital, Oslo.
"AMI leads to a permanent loss of contractile elements in the heart and the formation of fibrous scarring. Regeneration of contractile myocardium has been a target of cell therapy for more than a decade," he added.
According to Dr. Brinchmann, MSCs tolerate hypoxia, secrete angiogenic factors and have been shown to improve vascularization; thus, they have properties suggesting that they may beneficially impact AMI, chronic heart failure and angina pectoris after cell transplantation.
Following injection into the "border zone" and infarct area of immunodeficient rats one week after induced myocardial infarction, the researchers used echocardiography to measure myocardial function and other analyses to measure the size of scaring, density of blood vessels in the scar, and the health of myocardial tissues.
"Our results showed that intramyocardial injection of both ADSCs and SM-MSCs one week after AMI led to a substantial decrease in infarct size and a significant improvement in left ventricle function when compared with injections of cell culture medium alone," concluded the researchers.
"There was a trend toward better functional improvement in the SM-MSC group when compared to the ADSC group, but this did not reach significance," they added.
They concluded that many questions remain unanswered, including the question of whether MSCs isolated from different organisms could result in different functional outcomes.
Other unanswered questions relate to the optimal time delay between the onset of myocardial infarction and injection of MSCs. These cells do, however, still appear to be "a potentially interesting adjuvant treatment modality for selected patients following acute myocardial infarction," they concluded.
Read more from the original source:
Different organ-derived stem cell injections improve heart function in rats
Procedure Combines Point-of-Care Stem Cell Therapy and Enriched Mesenchymal Stem Cell Injection
NAMPA, ID--(Marketwire - Nov 29, 2012) - Veterinarians from Idaho Equine Hospital, including Dr. William Maupin and Dr. Stuart Shoemaker, performed the first-ever combination regenerative medicine treatment on a six-year-old Quarter Reined Cow horse that suffered a significant injury to its distal straight sesamoidean ligament.
This injury can be challenging for veterinarians to successfully treat and return the horse to athletic competition.
The veterinary team and the scientific team at Stemlogix, LLC determined that the best treatment protocol would be to treat him with point-of-care stem cell therapy using the Stemlogix In-Clinic Regenerative Medicine System and then perform a follow up treatment a few weeks later using culture expanded mesenchymal stem cells. He received a dose of the point-of-care stem cell therapy three weeks ago and three weeks later received an injection of culture expanded mesenchymal stem cells.
Stemlogix, LLC pioneered the landmark stem cell therapy treatment regimen and this is the first time this combination stem cell therapy treatment has ever been performed on a horse. The team that treated the horse believes this revolutionary treatment protocol will give him the best chance for an improved quality of life and provides the best opportunity for restoring the injured tissue back to its normal structure instead of healing with scar tissue.
"Due to the severity of the injury and the poor circulation present in the sesamoidean ligament we elected to perform a two-step therapeutic approach," said Dr. Maupin. "We first injected adipose derived stem cell therapy produced patient-side to initiate an environment of healing.
"In addition, we injected culture expanded mesenchymal stem cells. This secondary expanded and enriched mesenchymal stem cell therapy treatment may further restore normal tissue structure or actual ligament tissue."
To provide him with this groundbreaking treatment, two small fat samples were taken from the base of his tail via a minimally invasive lipoaspirate procedure. Fat tissue is the richest source of stem cells for both human patients and animal patients. One of the tissue samples was processed on-site to provide a same-day, point-of-care stem cell treatment while the other tissue sample was sent to the Stemlogix state-of-the-art cGMP laboratory where the mesenchymal stem cells were isolated and expanded for three weeks. A portion of his stem cells were also cryopreserved for future use.
The Stemlogix In-Clinic Regenerative Medicine System rapidly produces a composition of stem cells at the point-of-care containing an abundance of mesenchymal stem cells, endothelial progenitor cells, among other cell types. This assortment of stem cells provides additional growth factors and therapeutic proteins to stimulate healing. This system offers veterinarians an optimal treatment tool that is convenient and effective in treating debilitating equine diseases and injuries.
On the other hand, the culture expanded stem cell therapy contains a high number of purified mesenchymal stem cells which makes this therapy better suited for treating specific indications such as orthopedic injuries, autoimmune diseases and other degenerative diseases. Mesenchymal stem cells are multi-potent or have the ability to form into a variety of new tissues such as bone, cartilage, ligaments, and tendons.
See the original post:
Stemlogix Reports Idaho Veterinarians Perform First in U.S. Combination Regenerative Medicine Treatment on Injured Horse
CARLSBAD, CA--(Marketwire - Nov 29, 2012) - International Stem Cell Corporation ( OTCQB : ISCO ) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based biotechnology company focused on the development of therapeutic products, today announced the achievement of a critical milestone towards the clinical development of its stem cell therapy.
The Company's research and development team has created the world's first human clinical-grade stem cell lines with the ability to immune-match millions of individuals. ISCO's existing research-grade parthenogenetic stem cell lines, one of which contains the most common immune type in the Caucasian population and may be an immune-match to approximately 70 million people, are used in pre-clinical development. These new clinical-grade stem cell lines position ISCO to be able to conduct clinical trials in the United States.
Dr. Semechkin, CEO and Co-Chairman of the Board, comments, "We've been working diligently for three years to perfect this technology, which was first developed by our scientific founder, Dr. Elena Revazova in Moscow, and I'm excited to report that we have been able to derive new stem cell lines in the United States under the US and California regulatory frameworks. I'm optimistic that the new parthenogenetic stem cell lines, by providing a potentially unlimited supply of cells and tissue for transplantation, will be of great benefit to the medical community and patients world-wide."
The new stem cell lines, created using ISCO's proprietary technology, are the first of a new generation of clinical-grade human parthenogenetic stem cell (hpSC) lines created in the United States under US regulatory oversight and designed to meet FDA regulations. The US Food and Drug Administration developed Good Tissue Practice (GTP) and Good Manufacturing Practice (GMP) standards to ensure the safety of products developed for clinical use. Conforming to GMP is extremely important as it means that the cells can be used in clinical development programs.
The new lines have been confirmed by independent third-party testing to be "homozygous" in the HLA coding regions meaning that they have a simple genetic profile in the critical areas of the DNA that code for immune rejection. This feature is one of the most important differences of hpSC when compared with embryonic stem cells and a distinct clinical advantage because of their ability to be immune-matched to the patient. We expect the new lines to immune-match millions of individuals, and will be added to ISCO's existing bank providing a platform from which to develop cells and tissue for clinical use.
"The importance of this breakthrough cannot be overstated," commented Dr. Craw, Executive Vice President of ISCO. "Expanding our collection is not only important for our therapeutic programs, but also further establishes our leadership position in human stem cell technology. Achieving this critical milestone moves us along the path to make the transition into a clinical stage company."
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs) hence avoiding ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at http://www.internationalstemcell.com.
To receive ongoing corporate communications via email, visit: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: http://www.facebook.com/InternationalStemCellCorporation and http://www.twitter.com/intlstemcell
Original post:
International Stem Cell Corporation Announces Significant Progress Towards Clinical Development
A panel at the Harvard Law School Wednesday discussed the ethical debate over the use of embryonic stem cells in the United States, focusing on the burgeoning controversy surrounding the role of stem cell therapy in medical tourism.
Medical tourism, in which patients travel internationally to gain access to specific health care services, has become increasingly common, panelists said. They said that reasons for medical tourism range from basic hip replacement surgery to black market organ sales. As most stem cell therapies are not approved in the United States, numerous patients are going abroad to countries like China and Russia where treatment is legal.
Panelist I. Glenn Cohen, an assistant professor at the Law School, said that it was probable that a Chinese stem cell facility performs several hundred thousand of these treatments yearly. He said that numerous celebrities, including football quarterback Peyton Manning, have reportedly traveled abroad to receive stem cell treatment not approved by the FDA.
A number of facilities claim to use stem cells to cure a wide array of diseases. University of Alberta law professor Timothy Caulfield, another panelist, pointed out that a simple Google search leads potential patients to a plethora of websites which claim that diseases such as autism and cancer can be cured through stem cell therapy.
Its being offered as routine, its being offered as safe, its being offered as effective, Caulfield said, citing his own 2008 study on the subject, Of course, none of them being offered matched what the scientific literature said.
According to American history professor Jill Lepore, the hyper-acceleration of enthusiasm for stem cell therapy is reminiscent of a century ago when science journalism and government funding for science research began to blossom. Lepore pointed out how public excitement over scientific procedures has affected society in the past, popularizing cryonics research and the work of Eugene Steinach, who claimed his vasectomy operation reversed the aging process.
Panelists said that one issue with stem cell tourism is the number of health risks associated with such procedures, citing a number of instances where stem cell therapy caused serious harm.
They also noted that public discussion about stem cell therapy has been markedly positive, lending an air of legitimacy to stem cell therapy that hasnt been validated by research.
Articles criticizing stem cell tourism, on the other hand, have generally received a less favorable response. Caulfield told the audience that when he co-wrote an article in The Atlantic criticizing stem cell therapy, he was accused as being a nutball Canadian socialist bioethicist.
The panelists emphasized that more accurate information should be provided to the public regarding stem cell treatments.
Continued here:
Professors Critique Stem Cell Medical Tourism
SCMOM 2012_DiscGenics
DiscGenics trade; is a development stage spinal therapeutics company using adult human disc-derived stem cells and tissue engineering techniques to treat patients debilitated by degenerative disc disease (DDD). Back pain is the second most common reason to visit one #39;s doctor, and costs an estimated $100 billion in diagnosis, management, and lost productivity each year. From our patented culture method comes the Discophere trade;, a therapeutic cluster of stem/progenitor cells that have been shown to differentiate and excrete the biological components needed to regenerate an intervertebral disc. http://www.discgenics.com Presenter: Flagg Flanagan, CEO, DiscGenicsFrom:AllianceRegenMedViews:4 1ratingsTime:10:00More inScience Technology
More here:
SCMOM 2012_DiscGenics - Video
SCMOM 2012_AlloSource
AlloSource, a non-profit organization, offers more than 200 types of precise bone, skin, soft-tissue and custom-machined allografts for use in life-saving and life-enhancing medical procedures. The world #39;s leader in fresh cartilage tissue and skin allografts, the company developed a cleansing process for fresh tissue grafts that does not destroy live cells. Most recently, AlloSource created a technique to recover mesenchymal stem cells from cadaveric adipose tissue, which led to the development of its own stem cell product, AlloStem® Stem Cell Bone Growth Substitute. AlloSource is registered with the FDA, accredited by the American Association of Tissue Banks and is compliant with all applicable state regulations and with the ISO 9001:2008 standard. http://www.allosource.org Presenter: Kevin Cmunt, Executive Vice President, AlloSourceFrom:AllianceRegenMedViews:2 1ratingsTime:14:35More inScience Technology
See more here:
SCMOM 2012_AlloSource - Video
SCMOM 2012_Juventas Therapeutics
Juventas Therapeutics is a privately held, clinical-stage biotechnology company developing factor-based regenerative therapies to treat life-threatening diseases. The company #39;s lead product, JVS-100 encodes Stromal cell-Derived Factor-1 (SDF-1) which has been shown to protect and repair tissue following ischemic injury by recruiting the body #39;s own stem cells to the damaged tissue, preventing cell death and promoting new blood vessel growth. Through activating natural stem cell based repair pathways within the patient, we eliminate the cost and complexity associated with current cellular therapies. Juventas is currently enrolling two Phase II clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients. http://www.juventasinc.com Presenter: Rahul Aras, President and CEO, Juventas TherapeuticsFrom:AllianceRegenMedViews:10 1ratingsTime:15:10More inScience Technology
Go here to see the original:
SCMOM 2012_Juventas Therapeutics - Video